Diabetes & Endocrinology – Page 9

Intermittent Fasting in Overweight and Obese Postmenopausal Women with Rheumatoid Arthritis: Insights from a Randomized Controlled Trial

By MedXY 08/08/2025

A recent RCT suggests intermittent fasting may improve physical function and disease activity in overweight and obese postmenopausal women with RA, but shows no significant effect on inflammation or oxidative stress markers.

Clinical Updates Diabetes & Endocrinology news Respiratory Specialties

Clinical Advances in Akkermansia muciniphila-Based Interventions: Respiratory Symptom Relief, Muscle Strength Enhancement, and Obesity Management

By MedXY 08/08/2025

Recent clinical trials reveal the therapeutic potential of Akkermansia muciniphila strains in alleviating respiratory symptoms, improving muscle strength, and preventing diet-induced obesity in dogs.

Clinical Updates Diabetes & Endocrinology Family Medicine & Nutrition news Specialties

Personalized Probiotic Therapy: Akkermansia muciniphila Supplementation in Overweight and Obese Type 2 Diabetes—Baseline Levels Matter

By MedXY 08/08/2025

Akkermansia muciniphila supplementation improves metabolic outcomes in overweight/obese type 2 diabetes patients only when baseline gut levels are low, underscoring the need for personalized microbiota-guided interventions.

Clinical Updates Diabetes & Endocrinology news OB/GYN & Women's Health Specialties

Unveiling the Link Between Low-Dose Cadmium Exposure and Gestational Diabetes Mellitus: Mechanistic Insights from Placental Models

By MedXY 08/06/2025

Low-dose cadmium exposure during early pregnancy is strongly associated with increased risk of gestational diabetes mellitus, likely via placental metabolic and hormonal alterations.

Clinical Updates Diabetes & Endocrinology news Specialties

Semaglutide Shows Promise in Type 1 Diabetes with Obesity: Insights from the ADJUST-T1D Trial

By MedXY 08/05/2025

Semaglutide significantly improved glycemic control and weight loss in adults with type 1 diabetes and obesity, without increasing major safety risks, according to the ADJUST-T1D trial.

Diabetes & Endocrinology Family Medicine & Nutrition news Specialties

How Should Diabetic Patients Eat Fruits?

By MedXY 08/05/2025

Guidance on fruit consumption for diabetic patients, focusing on fruit types, portion control, timing, and blood sugar monitoring to maintain stable glucose levels.

Diabetes & Endocrinology Family Medicine & Nutrition news Specialties

How Should Diabetic Patients Consume Fruits?

By MedXY 08/05/2025

This article guides diabetic patients on choosing appropriate fruits based on glycemic index and load, portion control, timing, and blood sugar monitoring for optimal health management.

Clinical Updates Diabetes & Endocrinology Internal Medicine news Psychiatry Specialties

Dissecting Depression in Diabetes: Distinct Links of Somatic and Cognitive Symptoms with Inflammation and Insulin Resistance

By MedXY 08/03/2025

New GRADE sub-study reveals that somatic symptoms of depression, not cognitive-affective symptoms, are chiefly associated with inflammation and insulin resistance in type 2 diabetes, highlighting a pathophysiological bridge for targeted interventions.

Clinical Updates Diabetes & Endocrinology news Psychiatry Specialties

Semaglutide for Weight Management in Clozapine-Treated Schizophrenia: Results from the COaST Phase 2 RCT in Australia

By MedXY 08/03/2025

Semaglutide significantly reduced body weight without impacting psychotic symptoms or clozapine levels in people with schizophrenia and obesity on clozapine therapy.

Clinical Updates Diabetes & Endocrinology news Specialties

Continuous Glucose Monitoring in Gestational Diabetes: Insights from the DipGluMo Randomized Controlled Trial in Switzerland

By MedXY 08/02/2025

The DipGluMo trial found that real-time continuous glucose monitoring does not improve perinatal outcomes versus self-monitoring in gestational diabetes, but is preferred by patients for ease of use.

Clinical Updates Diabetes & Endocrinology news Oncology Specialties

Postoperative Radioiodine Ablation in Low-Risk Differentiated Thyroid Cancer: Insights from the IoN Trial

By MedXY 08/02/2025

The IoN trial demonstrates that postoperative radioiodine ablation can be safely omitted in most patients with low-risk differentiated thyroid cancer after total thyroidectomy, without compromising recurrence-free survival.

Clinical Updates Diabetes & Endocrinology news Specialties

Amycretin: A Novel Unimolecular GLP-1 and Amylin Receptor Agonist for Obesity – Early-Phase Clinical Insights and Broader GLP-1 Drug Development Perspective

By MedXY 08/02/2025

Amycretin, a new unimolecular GLP-1 and amylin agonist, demonstrated significant weight loss and acceptable tolerability in a phase 1b/2a study, underscoring its potential as an anti-obesity therapy.

Clinical Updates Diabetes & Endocrinology news Specialties

Retatrutide in Type 2 Diabetes and MASLD: Integrative Evidence on Body Composition and Liver Fat Reduction

By MedXY 08/02/2025

Retatrutide, a triple hormone receptor agonist, significantly reduces body fat and liver fat in patients with type 2 diabetes and MASLD, with a favorable safety profile and preservation of lean mass.

Clinical Updates Diabetes & Endocrinology news Specialties

Once-Weekly Insulin Regimens in Type 2 Diabetes: Comparative Efficacy, Safety, and Clinical Implications from COMBINE 3 and QWINT Trials

By MedXY 08/02/2025

Once-weekly insulin regimens (IcoSema, efsitora alfa) demonstrate non-inferior glycemic control compared to daily injections in type 2 diabetes, with advantages in hypoglycemia risk, weight, and injection burden.

Clinical Updates Diabetes & Endocrinology news Specialties

Automated Insulin Delivery in Young Children with Type 1 Diabetes: Insights from the LENNY Trial

By MedXY 08/02/2025

The LENNY trial demonstrates that the MiniMed 780G automated insulin delivery system improves glycaemic control and maintains safety in children aged 2–6 years with type 1 diabetes.

Clinical Updates Diabetes & Endocrinology news Specialties

Oveporexton: A Promising Orexin Receptor 2 Agonist for Narcolepsy Type 1 – Results from a Phase 2 Randomized Trial

By MedXY 08/02/2025

Oveporexton, an oral orexin receptor 2–selective agonist, demonstrated significant improvements in wakefulness and cataplexy in narcolepsy type 1 patients over 8 weeks, with manageable adverse events.

Clinical Updates Diabetes & Endocrinology news Specialties

Inebilizumab for Generalized Myasthenia Gravis: Results from a Phase 3 Randomized Trial

By MedXY 08/01/2025

A phase 3 trial shows inebilizumab, a CD19+ B-cell depleting antibody, improves function and reduces disease severity in generalized myasthenia gravis without increasing serious adverse events.

Clinical Updates Diabetes & Endocrinology news Specialties

FDA Approves Once-Weekly Skytrofa (Lonapegsomatropin-tcgd) for Adult Growth Hormone Deficiency: Clinical Implications and Evidence Review

By MedXY 07/31/2025

Skytrofa, a once-weekly injectable growth hormone, is FDA-approved for adult GHD, offering improved adherence and positive metabolic outcomes. Clinical trials show superior efficacy and favorable safety compared to daily somatropin.

Diabetes & Endocrinology news Specialties

Advances in Obesity and Diabetes Management: Highlights from ADA 2025

By MedXY 07/31/2025

New weight-loss drug combinations, oral semaglutide cardiovascular outcomes, inhaled insulin for type 1 diabetes, and benefits of switching from diet drinks to water were key ADA 2025 findings.

Clinical Updates Diabetes & Endocrinology news Ophthalmology Specialties

Veligrotug Emerges as a Promising Therapy for Thyroid Eye Disease: Insights from the THRIVE and THRIVE-2 Trials

By MedXY 07/31/2025

Veligrotug demonstrates robust efficacy and manageable safety in both active and chronic thyroid eye disease, positioning itself as a potential alternative to teprotumumab based on phase 3 THRIVE trial data.